Overall and regional baseline characteristics of participants included in the diagnostic delay analysis
| Variables . | Mean ± s.d. or n (%) . | |||||
|---|---|---|---|---|---|---|
| Total . | Europe . | North America . | Latin America . | Asia . | South Africa . | |
| Gender: female | 3080 (55.4) | 2049 (58.7) | 479 (62.3) | 307 (56.0) | 125 (20.8) | 120 (82.2) |
| Education level: university | 2569 (46.2) | 1667 (47.7) | 445 (57.8) | 221 (40.3) | 182 (30.3) | 54 (37.0) |
| Age at symptom onset | 26.8 ± 11.3 | 26.2 ± 10.8 | 26.4 ± 12.1 | 30.5 ± 12.9 | 26.9 ± 10.7 | 26.7 ± 11.4 |
| Age at diagnosis | 34.2 ± 11.4 | 33.9 ± 11.0 | 35.3 ± 12.8 | 36.5 ± 11.4 | 31.0 ± 10.4 | 37.5 ± 10.8 |
| Diagnostic delay | 7.4 ± 9.0 | 7.7 ± 8.8 | 9.0 ± 11.0 | 5.9 ± 8.6 | 4.2 ± 5.4 | 10.8 ± 10.6 |
| Symptom duration | 17.1 ± 13.3 | 18.4 ± 13.6 | 18.0 ± 14.4 | 13.7 ± 11.2 | 11.6 ± 9.3 | 18.0 ± 12.7 |
| Diagnosed by rheumatologist | 3842 (72.1) | 2499 (76.5) | 511 (66.4) | 407 (74.3) | 323 (53.8) | 102 (70.8) |
| No. of HCPs seen before diagnosis | 2.3 ± 1.3 | 2.4 ± 1.4 | 2.6 ± 1.5 | 2.2 ± 1.2 | 1.6 ± 0.9 | 2.0 ± 1.1 |
| HLA-B27: positive | 2464 (71.1) | 1559 (70.6) | 340 (73.0) | 228 (65.1) | 254 (78.2) | 83 (72.2) |
| Uveitis | 1171 (23.2) | 670 (21.1) | 215 (30.8) | 121 (24.8) | 131 (23.8) | 35 (25.2) |
| Psoriasis | 461 (20.4) | 265 (23.0) | 46 (26.3) | 109 (22.9) | 25 (7.9) | 16 (11.9) |
| IBD | 724 (14.0) | 391 (11.9) | 128 (18.3) | 84 (17.5) | 88 (16.1) | 33 (24.1) |
| Variables . | Mean ± s.d. or n (%) . | |||||
|---|---|---|---|---|---|---|
| Total . | Europe . | North America . | Latin America . | Asia . | South Africa . | |
| Gender: female | 3080 (55.4) | 2049 (58.7) | 479 (62.3) | 307 (56.0) | 125 (20.8) | 120 (82.2) |
| Education level: university | 2569 (46.2) | 1667 (47.7) | 445 (57.8) | 221 (40.3) | 182 (30.3) | 54 (37.0) |
| Age at symptom onset | 26.8 ± 11.3 | 26.2 ± 10.8 | 26.4 ± 12.1 | 30.5 ± 12.9 | 26.9 ± 10.7 | 26.7 ± 11.4 |
| Age at diagnosis | 34.2 ± 11.4 | 33.9 ± 11.0 | 35.3 ± 12.8 | 36.5 ± 11.4 | 31.0 ± 10.4 | 37.5 ± 10.8 |
| Diagnostic delay | 7.4 ± 9.0 | 7.7 ± 8.8 | 9.0 ± 11.0 | 5.9 ± 8.6 | 4.2 ± 5.4 | 10.8 ± 10.6 |
| Symptom duration | 17.1 ± 13.3 | 18.4 ± 13.6 | 18.0 ± 14.4 | 13.7 ± 11.2 | 11.6 ± 9.3 | 18.0 ± 12.7 |
| Diagnosed by rheumatologist | 3842 (72.1) | 2499 (76.5) | 511 (66.4) | 407 (74.3) | 323 (53.8) | 102 (70.8) |
| No. of HCPs seen before diagnosis | 2.3 ± 1.3 | 2.4 ± 1.4 | 2.6 ± 1.5 | 2.2 ± 1.2 | 1.6 ± 0.9 | 2.0 ± 1.1 |
| HLA-B27: positive | 2464 (71.1) | 1559 (70.6) | 340 (73.0) | 228 (65.1) | 254 (78.2) | 83 (72.2) |
| Uveitis | 1171 (23.2) | 670 (21.1) | 215 (30.8) | 121 (24.8) | 131 (23.8) | 35 (25.2) |
| Psoriasis | 461 (20.4) | 265 (23.0) | 46 (26.3) | 109 (22.9) | 25 (7.9) | 16 (11.9) |
| IBD | 724 (14.0) | 391 (11.9) | 128 (18.3) | 84 (17.5) | 88 (16.1) | 33 (24.1) |
HCP: healthcare professional.
Overall and regional baseline characteristics of participants included in the diagnostic delay analysis
| Variables . | Mean ± s.d. or n (%) . | |||||
|---|---|---|---|---|---|---|
| Total . | Europe . | North America . | Latin America . | Asia . | South Africa . | |
| Gender: female | 3080 (55.4) | 2049 (58.7) | 479 (62.3) | 307 (56.0) | 125 (20.8) | 120 (82.2) |
| Education level: university | 2569 (46.2) | 1667 (47.7) | 445 (57.8) | 221 (40.3) | 182 (30.3) | 54 (37.0) |
| Age at symptom onset | 26.8 ± 11.3 | 26.2 ± 10.8 | 26.4 ± 12.1 | 30.5 ± 12.9 | 26.9 ± 10.7 | 26.7 ± 11.4 |
| Age at diagnosis | 34.2 ± 11.4 | 33.9 ± 11.0 | 35.3 ± 12.8 | 36.5 ± 11.4 | 31.0 ± 10.4 | 37.5 ± 10.8 |
| Diagnostic delay | 7.4 ± 9.0 | 7.7 ± 8.8 | 9.0 ± 11.0 | 5.9 ± 8.6 | 4.2 ± 5.4 | 10.8 ± 10.6 |
| Symptom duration | 17.1 ± 13.3 | 18.4 ± 13.6 | 18.0 ± 14.4 | 13.7 ± 11.2 | 11.6 ± 9.3 | 18.0 ± 12.7 |
| Diagnosed by rheumatologist | 3842 (72.1) | 2499 (76.5) | 511 (66.4) | 407 (74.3) | 323 (53.8) | 102 (70.8) |
| No. of HCPs seen before diagnosis | 2.3 ± 1.3 | 2.4 ± 1.4 | 2.6 ± 1.5 | 2.2 ± 1.2 | 1.6 ± 0.9 | 2.0 ± 1.1 |
| HLA-B27: positive | 2464 (71.1) | 1559 (70.6) | 340 (73.0) | 228 (65.1) | 254 (78.2) | 83 (72.2) |
| Uveitis | 1171 (23.2) | 670 (21.1) | 215 (30.8) | 121 (24.8) | 131 (23.8) | 35 (25.2) |
| Psoriasis | 461 (20.4) | 265 (23.0) | 46 (26.3) | 109 (22.9) | 25 (7.9) | 16 (11.9) |
| IBD | 724 (14.0) | 391 (11.9) | 128 (18.3) | 84 (17.5) | 88 (16.1) | 33 (24.1) |
| Variables . | Mean ± s.d. or n (%) . | |||||
|---|---|---|---|---|---|---|
| Total . | Europe . | North America . | Latin America . | Asia . | South Africa . | |
| Gender: female | 3080 (55.4) | 2049 (58.7) | 479 (62.3) | 307 (56.0) | 125 (20.8) | 120 (82.2) |
| Education level: university | 2569 (46.2) | 1667 (47.7) | 445 (57.8) | 221 (40.3) | 182 (30.3) | 54 (37.0) |
| Age at symptom onset | 26.8 ± 11.3 | 26.2 ± 10.8 | 26.4 ± 12.1 | 30.5 ± 12.9 | 26.9 ± 10.7 | 26.7 ± 11.4 |
| Age at diagnosis | 34.2 ± 11.4 | 33.9 ± 11.0 | 35.3 ± 12.8 | 36.5 ± 11.4 | 31.0 ± 10.4 | 37.5 ± 10.8 |
| Diagnostic delay | 7.4 ± 9.0 | 7.7 ± 8.8 | 9.0 ± 11.0 | 5.9 ± 8.6 | 4.2 ± 5.4 | 10.8 ± 10.6 |
| Symptom duration | 17.1 ± 13.3 | 18.4 ± 13.6 | 18.0 ± 14.4 | 13.7 ± 11.2 | 11.6 ± 9.3 | 18.0 ± 12.7 |
| Diagnosed by rheumatologist | 3842 (72.1) | 2499 (76.5) | 511 (66.4) | 407 (74.3) | 323 (53.8) | 102 (70.8) |
| No. of HCPs seen before diagnosis | 2.3 ± 1.3 | 2.4 ± 1.4 | 2.6 ± 1.5 | 2.2 ± 1.2 | 1.6 ± 0.9 | 2.0 ± 1.1 |
| HLA-B27: positive | 2464 (71.1) | 1559 (70.6) | 340 (73.0) | 228 (65.1) | 254 (78.2) | 83 (72.2) |
| Uveitis | 1171 (23.2) | 670 (21.1) | 215 (30.8) | 121 (24.8) | 131 (23.8) | 35 (25.2) |
| Psoriasis | 461 (20.4) | 265 (23.0) | 46 (26.3) | 109 (22.9) | 25 (7.9) | 16 (11.9) |
| IBD | 724 (14.0) | 391 (11.9) | 128 (18.3) | 84 (17.5) | 88 (16.1) | 33 (24.1) |
HCP: healthcare professional.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
